A ruling about wording, not disclosure
On 27 May 2026, South Africa's Advertising Regulatory Board (ARB) ruled that L'Oréal's La Roche-Posay brand was partially liable for a social media post by a dermatologist who had received a congratulatory gift from the company. The dermatologist's post referenced "acne" — and because acne is a recognised medical condition, the ARB found this amounted to an impermissible medical claim under the Cosmetics Advertising Code (bizcommunity.com). L'Oréal argued it could not be held responsible for wording it did not write. The ARB rejected that defense outright, holding that brands remain accountable for claims made by anyone who receives gifts, incentives, or other commercial benefit — regardless of who typed the words.
This is a meaningfully different question from the one influencer-marketing rules usually answer. Disclosure regimes — including South Africa's own Code of Advertising Practice, which requires paid or incentivised content to be clearly identifiable as advertising (arb.org.za) — ask whether an audience knew a post was commercial. This ruling asks something harder: once a commercial relationship exists, who owns the content of what the recipient says. The ARB's answer is that the brand does, even for a single Instagram story from someone who wasn't paid to produce marketing copy, but merely sent a gift box.
The same regulator, twice in five weeks
The La Roche-Posay decision was the second round of an ongoing dermocosmetics fight. On 22 April 2026, the ARB dismissed a challenge L'Oréal had brought against Beiersdorf's Eucerin, finding Eucerin's "SA's No.1 Dermatologist Recommended Brand" claim adequately substantiated by a 152-dermatologist Mindline survey (bizcommunity.com). Five weeks later, Beiersdorf returned the favor, complaining about La Roche-Posay's own "most recommended" claim. This time the ARB found the underlying research — a 141-dermatologist Ipsos barometer fielded between October 2025 and January 2026 — was itself solid. La Roche-Posay won on substantiation. It lost only on the gifted dermatologist's acne reference.
South Africa is not alone in scrutinizing this brand's dermatologist-endorsement marketing. In September 2025, the UK's Advertising Standards Authority partially upheld a complaint against La Roche-Posay's "#1 Dermatologist Recommended" claim there too — not on substantiation, which the ASA found adequate from a 73-to-78-dermatologist sample, but because the verification data was buried in a footer rather than clearly signposted, breaching CAP Code rule 3.35 (asa.org.uk). Two regulators, two different countries, two different theories of liability — but a shared instinct that dermatologist-credentialed marketing needs tighter tethering to evidence than ordinary beauty-influencer content.
The case for the ARB's approach
The steelman here is real. Cosmetics marketing that borrows medical authority — a dermatologist's white coat, their clinical vocabulary — carries more persuasive weight than an ordinary lifestyle post, precisely because consumers read it as expert opinion rather than paid promotion. If a brand can seed free product to dozens of dermatologists, knowing some meaningful share will post enthusiastically and occasionally stray into medical-condition language, and then disclaim responsibility for whichever posts cross a line, the Cosmetics Advertising Code's ban on medical claims becomes trivial to route around. Gifting at scale is not meaningfully different from a paid campaign if the expected outcome — favorable, medically-inflected content — is the same. Regulators policing this space have watched exactly this workaround proliferate globally, and closing it with a bright-line accountability rule is a defensible response to a real substitution effect.
Where the ruling overshoots
The trouble is the ARB collapsed two things that should carry different levels of brand fault. A paid influencer brief that instructs a dermatologist what to say is the brand's speech in every meaningful sense; strict liability there is uncontroversial. A congratulatory gift with no brief, no script, and no request for a post is a much thinner form of "commercial benefit" — yet the ARB treated the resulting, unsolicited wording as if L'Oréal had authored it. That standard gives brands no safe way to send goodwill gifts to healthcare professionals without assuming legal exposure for whatever those professionals independently choose to write, months or years later, about an unrelated skincare concern.
The practical effect will be to chill exactly the relationships regulators should want: brands will simply stop gifting to dermatologists, or will demand pre-clearance rights over any social media a recipient might ever post — a far more intrusive intervention into professional speech than requiring #ad disclosure ever was. A narrower rule — liability attaches when a brand solicits, reviews, or reasonably anticipates a specific post, but not for unprompted commentary from a gift recipient — would have closed the disclosure loophole the ARB was worried about without making every product-sampling relationship a latent liability. South Africa's Consumer Protection Act and Code of Advertising Practice already give the ARB tools to police coordinated campaigns; this ruling reaches further, into speech the brand neither wrote nor requested.
What to watch
Expect two things. First, more South African beauty brands quietly pulling back gifting programs to medical professionals rather than risk the same outcome. Second, an appeal or a narrowing clarification from the ARB's Appeal Committee, since a rule this broad is unlikely to survive contact with a case where the gift and the post are separated by months and any personal medical detail unrelated to the brand's products.